QRL 204
Alternative Names: QRL-204Latest Information Update: 24 Jun 2024
Price :
$50 *
At a glance
- Originator QurAlis Corporation
- Class Antidementias; Antisense oligonucleotides
- Mechanism of Action Gene silencing; UNC13B protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Frontotemporal dementia